

**Minutes of the September 10, 2010  
Pharmacy & Therapeutics (P&T) Committee Meeting  
SD Department of Social Services, Medical Services Division**

**Members present**

Bill Ladwig, R.Ph; Rick Holm, M.D.; Debra Farver, PharmD.; Verdayne Brandenburg, M.D.; Willis Sutliff, M.D.; Galen Goeden, R.Ph; Timothy Soundy, M.D.; Dennis Hedge, PharmD.

**Members absent**

Dana Darger, R.Ph; James Engelbrecht, M.D.

**DSS staff present**

Mike Jockheck, RPh.

**HID staff present**

Candace Rieth, Pharm.D.

**Administrative Business**

The P&T meeting was called to order by B. Ladwig at approximately 1:00pm. The minutes of the June 11, 2010 meeting were presented. W. Sutliff made a motion to approve. D. Farver seconded the motion. The motion was approved unanimously. V. Brandenburg, serving as vice-chair of the committee, ran the meeting in the chair's absence.

**Prior Authorization Update and Statistics**

The committee reviewed forms for medications that currently require prior authorization. B. Ladwig made a motion to include Xyzal on the antihistamine prior authorization form. G. Goeden seconded the motion. The motion was approved unanimously. G. Goeden made a motion to stop covering OTC proton pump inhibitors. B. Ladwig seconded the motion. The motion was approved unanimously. B. Ladwig made a motion to discontinue the generic statin tablet splitting program. G. Goeden seconded the motion. The motion was approved unanimously. No other changes were made to the forms for medications currently requiring prior authorization.

D. Farver asked for an update on the prior authorization for antipsychotics and antidepressants. M. Jockheck said that he would speak to L. Iversen and update the committee at the December meeting.

C. Rieth presented an overview of the prior authorization (PA) activity for July 2010. There were a total of 1,898 PAs processed in the month of July, with 99.74% of those requests responded to in less than 8 hours. There were 1,649 (87%) requests received electronically and 249 (13%) requests received by fax. In response to a request from the committee, C. Rieth presented the number of approvals and denials, by form type, for the faxed (manual) PA requests.

**Analysis of the Top 15 Therapeutic Classes**

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 04/01/2010 – 06/30/2010. The top five classes were antipsychotics, cerebral stimulants, amphetamines, beta-adrenergic agonists, and antidepressants. The top 15 therapeutic classes make up 41.49% of total claims.

**Patent Expiration and Pipeline Review**

C. Rieth presented patent expiration, first-time generics and pipeline information. The committee asked that the patent expiration list be condensed to only include items that could potentially lose patent during the next two years. The committee would like to see the complete list annually.

### **ADD/ADHD Review**

C. Rieth presented data and examples of restrictions in other states for medications used to treat ADD/ADHD. There was no public comment. T. Soundy made a motion to place Desoxyn on prior authorization. B. Ladwig seconded the motion. The motion was approved unanimously. T. Soundy made a motion to place a prior authorization on medications used to treat ADD/ADHD when a patient receives a prescription for more than two distinct chemical entities. B. Ladwig seconded the motion. There was no public comment. The motion was approved unanimously. M. Jockheck stated that this will become effective 30-60 days after the new point of sale system is implemented.

### **Opiate Agonist Review**

C. Rieth presented data and a prior authorization form for the opiate agonists. There was no public comment. A motion was made by B. Ladwig to place name brand narcotics on prior authorization and to include Darvon N-100. G. Goeden seconded the motion. The motion was approved unanimously.

### **High Cost/Low Utilization Drugs**

C. Rieth presented a table showing top drugs by dollar total over \$1,000 for 2009. There was no public comment. B. Ladwig made a motion to place a prior authorization on drugs over \$1,000. The list included in the P&T pack should be screened for medications that already require a prior authorization and criteria developed where appropriate. G. Goeden seconded the motion. The motion was approved unanimously. The updated list will be presented at the next meeting.

### **Metozolv ODT Review**

C. Rieth presented a prior authorization form for Metozolv ODT. W. Sutliff made a motion to place Metozolv ODT on prior authorization. B. Ladwig seconded the motion. There was no public comment. The motion was approved unanimously.

### **Statin Review**

C. Rieth presented clinical information and data for the statins. R. Holm made a motion to place all statins, except for simvastatin, on prior authorization with criteria of failure with two generics. T. Soundy seconded the motion. D. Farver made a motion to table. G. Goeden seconded the motion. Roll call was taken with 5 members agreeing to table the motion and 3 members opposed to tabling the motion. Motion was tabled. A motion was made by W. Sutliff to place Vytorin on prior authorization. G. Goeden seconded the motion. Luciano Kolodny, representing Merck, spoke against prior authorization of Vytorin. W. Sutliff withdrew his motion and asked that a compilation of studies be provided at the next meeting.

### **Soma 250 Review**

C. Rieth presented clinical information and data for Soma 250. B. Ladwig made a motion to place Soma 250 on prior authorization. D. Farver seconded the motion. There was no public comment. The motion was approved unanimously.

### **Multaq Review**

C. Rieth presented clinical information for Multaq. The topic was tabled.

### **Xyrem Review**

C. Rieth presented clinical information and data for Xyrem. T. Soundy made a motion to place Xyrem on prior authorization. D. Farver seconded the motion. There was no public comment. The motion was approved unanimously.

The next meeting date is scheduled for December 10, 2010. The location will be updated on the website as soon as possible. A motion was made by B. Ladwig at 2:50pm to adjourn the SD Medicaid P&T meeting. G. Goeden seconded the motion. Motion passed unanimously and the meeting was adjourned.